DAY 1, SUNDAY, NOVEMBER 18, 2018

13.00 – 18.30  REGISTRATION for ISRT 2018

14.00 – 16.00  **SCIENTIFIC SESSION 1**: NUCLEAR CARDIOLOGY
Moderators: Juhani Knuuti, Turku, Finland and Pietro Muto, Naples, Italy

14.00 – 14.30  O1 Revolution in cardiac imaging: Quantitative perfusion, inflammation and hybrid imaging  Juhani Knuuti, Turku, Finland

14.30 – 15.00  O4 Novel therapies of cardiac regeneration. How imaging can help in diagnosis, targeting and monitoring?  Seppo Ylä-Herttuala, Kuopio, Finland

15.00 – 15.30  O2 Imaging innervation. Finally clinical applications?  Albert Flotats, Barcelona, Spain

15.30 – 16.00  O3 Gauging cardiac repair, regeneration and inflammation with new molecular probes  James Thackeray, Hannover, Germany

16.00 – 16.30  COFFEE & TEA BREAK

16.30 – 18.45  **SCIENTIFIC SESSION 2**: NEW TRENDS IN ONCOLOGY AND PRECISION MEDICINE.
Moderators: Vivek Subbiah, MDACC, Houston, TX, USA and Homer Macapinlac, MDACC, Houston, TX, USA

16.30 – 16.55  O5 Personalized medicine and precision oncology, Vivek Subbiah, Investigational Cancer Therapeutics, UT MD Anderson Cancer Center

16.55 – 17.20  O6 Precision oncology in rare tumors: adopting the orphans, Roman Groisberg, Division of Medical Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA

17.20 – 17.45  O7 Optimizing patient selection for phase 1 clinical trials: lessons from targeted therapy and immunotherapy drug development, Shiraj Sen, Drug Development, Sarah Cannon Research Institute at HealthOne; Denver, CO, USA
Target discovery for precision oncology using large public databases, Jason Roszik, Department of Genomic Medicine, UT MD Anderson Cancer Center

Re-188 Lipiodol Liver Cancer Project – an update on current status, Ajit Shinto, Coimbatore, India

WARMTH CONGRESS DINNER 1

19.30 – 22.30 Restaurant Meripaviljonki

DAY 2, MONDAY, NOVEMBER 19, 2018

08.00 – 18.00 REGISTRATION for ISRT 2018

09.00 – 11.00 OPENING CEREMONY

Welcome Address Partha Choudhury, President-Elect, WARMTH

Opening Remarks Kalevi Kairemo, Congress President, ISRT-2018, WARMTH

Welcome Address Pirkko Mattila, Minister of Health, Finland

WARMTH Candle Lighting Ceremony WARMTH Board Members

AJIT PADHY ORATION Steven M. Larson, MSKCC, NY, USA

O10 “New Insights in Theragnostics”

presenter Andrew M. Scott, Melbourne, Australia

11.00 – 11.30 COFFEE & TEA BREAK

11.30 – 13.00 SCIENTIFIC SESSION 3: RADIOEMBOLISATION AND LIVER THERAPIES

Moderators: Patrick Flamen, Brussels, Belgium and Aviral Singh, Bad Berka, Germany
11.30 – 11.55 O11  Personalized SIRT based on predictive dosimetry, regional functional reserve measurement and molecular imaging, Patrick Flamen, Jules Bordet Institute, Brussels, Belgium

11.55 – 12.20 O9  Oncolytic viruses, Akseli Hemminki, University of Helsinki

12.20 – 12.40 O13  Biologic dosimetry in SIRT, Katherine Vallis, University of Oxford, UK

12.40 – 13.00 O14  Intra-arterial PRRT of SSTR-expressing liver tumors, Aviral Singh, Bad Berka, Germany

Posters:  P1  The quantitative analysis of post-selective internal radiation therapy (SIRT) $^{90}$Y microspheres PET/CT in hepatocellular carcinoma in comparison with $^{99m}$Tc-labelledd macroaggregated albumin (MAA) planar and SPECT/CT, Ngoc Ha Le, Tran Hung Dao Hospital, Ho Chi Minh City, Vietnam

13.00 – 14.00  LUNCH AT THE CONGRESS CENTER PAASITORNI

14.00 – 16.00  SCIENTIFIC SESSION 4: NEW RADIONUCLIDE THERAPIES / RADIATION HAZARDS/ SAFETY ISSUES
Moderators: Seigo Kinuya, Kanazawa, Japan and Kazuko Ohno, Fukushima, Japan

14.00 – 14.30 O15  Boron neutron capture therapy and world’s first accelerator-based BNCT facility at Southern Tohoku General Hospital, Yoshihiro Takai, Southern Tohoku BNCT Research Center, Japan

14.30 – 15.00 O16  What did we learn from the Fukushima accident? Ohtsura Niwa, Radiation Effects Research Foundation, Hiroshima/ Nagasaki, Japan

15.00 – 15.30 O17  Regulatory nuclear safety aspects, Linear No-Threshold Hypothesis of risk from low-level radiation exposure, Bennet S Greenspan, Society of Nuclear Medicine and Molecular Imaging, USA

PANEL-discussion: Regulatory/ nuclear safety aspects
Moderators: Seigo Kinuya, Kazuko Ohno and Bennet S Greenspan

Posters:  P2  Establishment of incident reporting programme and lesson learnt in unsealed radionuclide therapy, Noreen Marwat, Nuclear Medicine Oncology and Radiotherapy Institute, Pakistan
Practices across Pakistan how medical emergency is handled in case of patients who has undergone unsealed radionuclide therapy, Noreen Marwat, Nuclear Medicine Oncology and Radiotherapy Institute, Pakistan

16.00 – 16.30 COFFEE & TEA BREAK

16.30 – 18.15 SCIENTIFIC SESSION 5: PROSTATE CANCER: PSMA RADIOLIGAND THERAPY (PRLT) – WHAT DO WE KNOW AND WHAT IS NEW? Moderator: Richard P. Baum, Bad Berka, Germany

16.30 – 16.45 O18 Introduction to PRLT, Richard P. Baum

16.45 – 17.00 O19 Dosimetry following Lu-177 PSMA radioligand therapy and an insight into novel radionuclides for theranostics of prostate cancer, Aviral Singh, Bad Berka, Germany

17.00 – 17.15 O20 Dosimetry in PSMA radioligand therapy of metastasized prostate cancer using Lu-177 PSMA I&T and Lu-177 PSMA-617 Christiane Schuchardt, Bad Berka, Germany

17.15 – 17.45 O21 PSMA targeting and therapy trials in Australia, Andrew M. Scott, Melbourne, Australia

17.45 – 18.00 O22 Ac-225- and Bi-213- PSMA-617 radioligand therapy in patients with castration resistant prostate cancer, Mike Sathekge, Pretoria, South Africa

18.00 – 18.15 O23 [18F]AIF-PSMA-HBED-CC and 177Lu-PSMA-617 as a potential theragnostic tandem and comparison with 68Ga-PSMA-HBED-CC in high-risk prostate cancer patients at initial staging, Omar Alonso, CUDIM, Montevideo, Uruguay

Posters: P4 177Lutetium-prostate-specific membrane antigen radionuclide treatment of lymph node metastatic prostate cancer with PSA recurrence: A cohort study, Finn Edler von Eyben, Odense, Denmark

P5 Dosimetry in Molecular Radiotherapy - Bad Berka Experience, Christiane Schuchardt, Bad Berka, Germany

P6 Web-Monitoring Tool for 177Lutetium-PSMA Treatments in Prostate Cancer Patients, Kalevi Kairemo, Helsinki, Finland
18.25 Tram transportation to the City Hall in front of the Scandic Paasi hotel (Hakaniemi Square stop 0252)

WARMTH CONGRESS DINNER 2

19.00 – 20.30 CITY HALL of Helsinki, Mayor Reception

20.45 -21.45 Tram transportation from the City Hall (Market Square stop) to the Scandic Paasi hotel (Hakaniemi Square) including sightseeing in Helsinki

DAY 3, TUESDAY, NOVEMBER 20, 2018

08.00 – 08.45 REGISTRATION for ISRT 2018

8.45 – 11.00 SCIENTIFIC SESSION 6: THYROID CANCER – QUO VADIS?
Moderators: Mark Tulchinsky, PA; USA & Raihan Hussain, Dhaka, Bangladesh

Debating Controversies in Radioiodine Imaging and Therapy of Thyroid Cancer

8.45 – 9.00 O24 Introduction-thyroid cancer management, Mark Tulchinsky, Hershey, PA, USA

9.00 – 9.15 O25 Total vs. subtotal thyroidectomy. East, West, what’s the best?
Ilya V. Sleptsov, St. Petersburg, Russia

9.15 – 9.30 O26 Dosimetric approach of thyroid cancer, Henry Bom, Chonnam, South Korea

9.30 – 9.45 O27 Management of I-131 refractory thyroid cancer: a multimodality approach, Partha Choudhury, New Delhi, India

9.45 – 9.55 O28 Prevalence of genetic duet and its influence on the prognosis of differentiated papillary thyroid carcinoma patients, Sanjana Ballal, New Delhi, India

9.55 – 10.00 O29 Comments -thyroid cancer management, Raihan Hussain, Dhaka, Bangladesh

Panel discussion: Moderator Mark Tulchinsky

Panelists: Raihan Hussain, Henry Bom, Partha Choudhury and Ilya Sleptsov, St. Petersburg, Russia
10.05 – 10.30  "Radioiodine Imaging Before, After, Both or Neither ... and How?"

10.30 – 10.55  "Controversies in Radioiodine Side-Effects: Confusion About Salivary Damage and Secondary Malignancy"

Posters:

P7  Antithyroglobulin antibody as a marker of successful ablation therapy in differentiated thyroid cancer, Ayu Rosemeilia Dewi, Universitas Padjadjaran, Indonesia

P8  Importance of isolated raised thyroglobulin antibody in follow up and management of differentiated thyroid cancer, Ray Soumendranath, Tata Medical Center, Kolkata, India

P9  Contribution of manual fusion in thyroid cancer whole body study with I-131. Case Report, Mariela Agolti, Parana, Argentina

P10 Contribution of manual fusion in thyroid cancer whole body study with I-131, Mariela Agolti, Parana, Argentina

11.00 – 11.10  Lifetime Achievement Awards & Group Photo

Irene Virgolini, President, WARMTH & Kalevi Kairemo

11.10 – 11.30  COFFEE & TEA BREAK

11.30 – 13.00  SCIENTIFIC SESSION 7: PEPTIDE RECEPTOR/ NEW THERAPIES

Moderator: Irene Virgolini, Innsbruck, Austria

11.30 – 11.45 O30  Value of FDG in NET: importance of dual tracer imaging, Margarida Rodrigues Radischat, Innsbruck, Austria

11.45– 12.00 O31  Value of Re-PRRT in NET, Anna Yordanova, Bonn, Germany

12.00– 12.15 O32  PRRT in G3-NEN, Aviral Singh, Bad Berka, Germany

12.15– 12.35 O33  New peptides for PRRT in Non-NETs, Irene Virgolini, Innsbruck, Austria

12.35– 12.50 O34  Long-term side effects and quality of life, patients view Josh Mailman, San Francisco, USA
A correlation between c-Fos expression and radioiodine in breast cancer cell lines, Aisyah Ellyanti, Andalas University/Dr.M.Djamil Hospital, Indonesia

Posters: P11 First ex-vivo experience with I- radiation and radioguided surgery technique in meningioma and neuroendocrine patients, Chiara Maria Grana, European Institute of Oncology, Milan, Italy

P12 Lutetium-labelled DOTA-TOC and radionuclide therapy (PRRT) in China: First Experience, Feng Wang, Nanjing, China

P13 Developing neuropeptide Y (NPY) nanoconstructs as potential theranostic agents, Irfan Ullah Khan, Institute of Nuclear Medicine & Oncology, Lahore, Pakistan

13.00 – 14.00 LUNCH AT THE CONGRESS CENTER PAASITORNI

14.00 – 16.00 SCIENTIFIC SESSION 8: NEW ALPHA- THERAPIES

Posters: P14 Clinical case of benefit due to deviation in Ra-223 treatment schedule, Tatiana Kochetova, MRRC, Obninsk, Russia
Personalized molecular imaging with bone scintigraphy, NaF-PET, and FDG-PET for evaluation of osteosarcoma response to Radium-223, Kalevi Kairemo, Houston, TX, USA

Treatment response evaluation in soft-tissue osteosarcoma metastases using fluoride-18 (18F)-PET/CT radiomics analysis for 223Ra-therapy, Kalevi Kairemo, Houston, TX, USA

Substantiation of an individual therapeutic dose of 153Sm-oxabiphor for the treatment of bone metastases, Ganna Grushka, Grigorev Institute for Medical Radiology, Ukraine

Radionuclide therapy for bone pain palliation in anemic patients: role of erythropoietin, Sukanta Barai, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India

18F-fluoroethyltyrosine PET/CT: the European Institute of Oncology experience in brain tumors, Chiara Maria Grana, European Institute of Oncology, Milan, Italy

Pharmaceutical development of the therapeutic radiopharmaceutical based on –emitting Sm-153 in heat-sensitive carrier for brachytherapy of tumors of various locations, NM Tolbit, Karpov Institute, Obninsk, Russia

15.50 – 16.20 COFFEE & TEA BREAK

16.20 – 17.00 SCIENTIFIC SESSION 9: FUTURE ASPECTS OF COLLABORATION OF WARMTH, IAEA AND WFNMB – ROUND TABLE DISCUSSION
Moderator: Irene Virgolini, Innsbruck, Austria

WARMTH perspective, Partha Choudhury, President-Elect

IAEA Perspective, NN, Vienna

WFNMB perspective, Andrew M. Scott, Melbourne, Australia

SNMMI perspective, Bennett Greenspan, USA

O41 Presentation of ICRT 2019, Feng Wang, Nanjing, China

O42 Closing remarks, Kalevi Kairemo